A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
Public ClinicalTrials.gov record NCT06158854. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Phase 1/2 Study Evaluating the Safety and Efficacy of Etentamig (ABBV-383) in AL Amyloidosis
Study identification
- NCT ID
- NCT06158854
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 76 participants
Conditions and interventions
Conditions
Interventions
- ABBV-383 (Etentamig) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2024
- Primary completion
- Aug 31, 2031
- Completion
- Aug 31, 2031
- Last update posted
- Dec 16, 2025
2024 – 2031
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sylvester Comprehensive Cancer Center - University of Miami /ID# 255856 | Miami | Florida | 33136 | Recruiting |
| Boston Medical Center /ID# 255066 | Boston | Massachusetts | 02118 | Recruiting |
| Mayo Clinic - Rochester /ID# 255258 | Rochester | Minnesota | 55905-0001 | Recruiting |
| Icahn School of Medicine at Mount Sinai /ID# 255408 | New York | New York | 10029 | Recruiting |
| Columbia University Medical Center /ID# 255068 | New York | New York | 10032-3729 | Recruiting |
| Memorial Sloan Kettering Cancer Center-Koch Center /ID# 255073 | New York | New York | 10065-6007 | Recruiting |
| Atrium Health Levine Cancer Institute /ID# 255074 | Charlotte | North Carolina | 28204 | Recruiting |
| Atrium Health Wake Forest Baptist Medical Center /ID# 255851 | Winston-Salem | North Carolina | 27157 | Recruiting |
| Oregon Medical Research Center /ID# 255119 | Portland | Oregon | 97239 | Recruiting |
| University of Washington /ID# 261581 | Seattle | Washington | 98109 | Recruiting |
| Wisconsin Medical Center /ID# 255836 | Milwaukee | Wisconsin | 53226 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06158854, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 16, 2025 · Synced May 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06158854 live on ClinicalTrials.gov.